Table 3 Cell cycle distribution of WiDr, H630 and SW1116 cells following OHP and/or TFT exposure

From: Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells

 

Cell cycle distribution

Drug treatment

(%) G1

(%) S

(%) G2M

WDr

 Control

46.8±3.0

15.2±0.9

38.0±2.9

 OHP IC75 48 h

25.8±2.6

21.4±1.8

52.8±3.9

 TFT IC75 48 h

3.4±0.6**

59.9±3.4**

36.7±3.1*

 TFT IC75+OHP IC75 48 h

18.1±4.1

53.4±6.0**

28.5±3.1**

 preTFT>OHP IC75 48 h

30.3±1.0

25.4±4.3

44.3±5.2

 preTFT>TFT IC75+OHP IC75 48 h

6.4±2.0**

55.2±4.9**

38.4±3.3*

H630

 Control

38.9±1.2

24.2±0.9

36.9±2.0

 OHP IC75 48 h

19.8±7.9

37.1±3.2

43.1±5.0

 TFT IC75 48 h

12.1±5.7

43.9±7.1

44.1±5.9

 TFT IC75+OHP IC75 48 h

13.6±3.5

49.1±2.6*

37.3±0.9

 preTFT>OHP IC75 48 h

26.0±1.4

30.6±1.9

43.4±2.9

 preTFT>TFT IC75+OHP IC75 48 h

11.5±3.7

52.7±0.8**

35.8±3.5

SW1116

 Control

46.9±2.6

23.2±2.0

29.9±0.7

 OHP IC75 48 h

30.5±1.9

41.7±3.0

27.8±1.6

 TFT IC75 48 h

8.5±1.1**

35.8±2.5

55.7±2.1**

 TFT IC75+OHP IC75 48 h

12.7±1.2**

49.2±2.2

38.1±2.6*

 preTFT>OHP IC75 48 h

12.6±0.8**

36.1±2.9

51.3±3.7**

 preTFT>TFT IC75+OHP IC75 48 h

9.3±0.3**

50.8±4.1

39.9±4.4*

  1. The cells were exposed 48 h to [IC75] of OHP, TFT or both drugs. These drug concentrations are mentioned in the legend of Table 2. preTFT: 4 h TFT pre-incubation period. Values are means±s.e.m. (n=3). Significant differences compared to OHP alone: *P<0.05; **P<0.01.
Back to article page